When: Breakout above $152.67 on volume > 7M shares with MACD bullish re-cross

Then: 50% scaled size of trimmed amount

When: Reclaim 10 EMA at $150.12 with positive MACD histogram

Then: Coil resolving bullishly; constructive signal for residual position

When: Failure to reclaim 10 EMA at $150.12 on next rally

Then: Momentum breakdown confirmed; reassess toward deeper trim

Hold core position with 10-15% trim to reduce earnings volatility; hard stop at $141.98

• Golden cross remains in force: 50 SMA above 200 SMA, both rising, price 5% above 50-day MA
• ATR compressed from 4.13 to 3.49 (~15% volatility contraction) indicates a coil, not a collapse
• Immunomedics impairment is a $12.6B non-cash write-down with zero impact on dividend ($1B/quarter) or FCF ($9.77B TTM)
• Normalized profit margin sustained at 25-30% despite headline net loss of -$10.5B
• Debt-to-equity at 223% is industry typical for large cap pharma with long-dated note structure
• Forward P/E of 14.6x is below S&P 500 average (~20x) despite defensive characteristics
• PEG ratio of 2.19 is appropriate for sub-1 beta, 2.22% dividend yield, 80% gross margin name
• Institutional ownership provides stability; absence of retail/meme narrative is a feature, not a bug
• Rotation into cleaner names creates transaction costs, tax events, and full-multiple entry points

→ vs aggressive: Selling 30-50% into a coiled, intact uptrend on a single lagging indicator is reactive, not proactive; coils resolve in both directions and the structural weight favors upside

→ vs aggressive: The $12.6B impairment is accounting optics, not economic reality—no cash outflow, no dividend impact, no FCF impact, no operating franchise impact

→ vs aggressive: 14.6x forward P/E is below S&P 500 average (~20x) and 2.19 PEG is appropriate for a low-beta defensive compounder with high FCF conversion; PEG=2 is not a hard ceiling

→ vs aggressive: Zero narrative cushion is a feature for institutional holders; retail chatter creates meme-driven volatility, which is irrelevant for this profile

→ vs aggressive: Rotation into 'cleaner' names is operationally messy, incurring transaction costs, potential tax events, and buying the alternative at full multiple ahead of its own binary events

→ vs aggressive: Preemptively selling on assumed Q3 miss is a directional bet, not risk management; in quality defensive names, modest misses are absorbed and position sizing should absorb binary events

REDUCE POSITION BY 20-25% INTO BINARY CATALYST; KEEP STOP AT 141.98; RE-ENTER ON PULLBACK TO 150 OR BREAKOUT ABOVE 152.67 WITH EXPANDING VOLUME

• RSI at 54.15 is neutral (midpoint), not overbought or oversold
• Stock rallied 17% off August bottom in seven weeks; 13 sessions of MACD cooling is normal reset, not exhaustion
• Golden cross intact (50 and 200 SMAs rising); 50 SMA at 141.98 is key structural support
• 10 EMA at 150.12 now acting as overhead resistance; middle Bollinger lost on October 2nd
• Lower Bollinger at 142.99; October 2nd low at 144.74 represents 5.2% pullback from September 22 high
• Immunomedics impairment is 12.6 billion non-cash write-down with no cash outflow; dividend held
• FCF at 9.77 billion on trailing basis; dividend covered 2.4x by FCF
• 80% gross margins with massive FCF conversion support premium valuation
• Forward P/E at 14.6x reasonable for low-beta compounder with dividend; PEG of 2.19 is premium but typical for quality names
• Binary catalyst (earnings) in 2-3 weeks poses real risk requiring position size adjustment
• 10-15% trim too small to meaningfully reduce earnings event risk; 30-50% trim too large given structural support
• Re-entry conditions: successful retest of 50 SMA with MACD histogram flipping positive, OR breakout above 152.67 on expanding volume

→ vs aggressive: MACD cooling over 13 sessions is normal post-rally reset, not momentum exhaustion; RSI is diverging bearishly from price highs as exhaustion would require; coils resolve both ways and 50 SMA at 141.98 hasn't confirmed breakdown

→ vs aggressive: 12.6 billion impairment is non-cash GAAP optics, not economic reality; FCF intact at 9.77 billion with 2.4x dividend coverage; market looks through non-cash impairments for pharma compounders

→ vs aggressive: PEG of 2.19 is not a hard ceiling for low-beta compounders with 80% gross margins and massive FCF conversion; premium PEG is norm, not exception for quality names

→ vs conservative: Ten to fifteen percent trim is too small to meaningfully change risk profile; 85-90% of position still exposed to binary outcome with tight stop is token gesture, not risk management

→ vs conservative: Conservative analyst assumes upward coil resolution because structural trend points up; that's probabilistic assumption dressed as analysis, not certainty

→ vs conservative: Absence of retail chatter does not insulate stock from 5-10% drawdown on bad earnings print; institutions de-risk before binary events too